Exozymes Inc. (EXOZ) stock
Close on Nov 11, 2026Market cap $37.13MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $37.13M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 10.16
- Dividend yield
- –
- Free cash flow yield
- -19.24%
Fundamentals
- Net income
- -$10.19M
- EPS, diluted
- -$1.20
- Free cash flow
- -$7.14M
- Book value per share
- $0.42
- Diluted shares
- 9M
Trading
- Previous close
- $4.04
- Open
- $4.16
- Day's range
- $3.91 – $4.16
- Volume
- 9,406
- Average volume (20 days)
- 14,277
- Beta (5 years)
- 1.23
- 52-week range
- $3.24 – $17.57
- RSI (14 days)
- 39.7
- Volatility (1 year)
- 78.1%
- Relative volume
- 1.06×
- WACC
- 11.0%
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | EXOZ | S&P 500 | Difference | EXOZ per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -23.8% | -2.4% | −21.4 pts | ||
| 3 months | -30.6% | -1.2% | −29.4 pts | ||
| Year to date | -63.3% | +12.3% | −75.6 pts | ||
| 1 year | -73.6% | +12.4% | −86.1 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Exozymes filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- Update
- Update
- News
- News
About Exozymes
Biological Products, (No Diagnostic Substances)
eXoZymes Inc. is a biomanufacturing platform company that develops cell-free biosolutions to produce chemicals and small-molecule active ingredients. The company leverages artificial intelligence and bioengineering to design stabilized enzyme catalysts, termed exozymes, which operate outside living cells within bioreactors to convert feedstocks into valuable compounds. Its primary commercial focus targets low-volume, high-value natural products and derivatives for the nutraceutical sector that possess potential application as active pharmaceutical ingredients. Additionally, the company develops specialized programs including an exozyme pathway for isobutanol production to support sustainable aviation fuels and industrial chemical applications. Its customers and collaborative partners comprise commercial entities in the nutraceutical and pharmaceutical industries, as well as government agencies supporting applied research.
Company profile, executives and historyExozymes stock: common questions
What is Exozymes's stock price?
EXOZ closed at $4.00 on Nov 11, 2026, down 0.99% on the day. Over the past 52 weeks it traded between $3.24 and $17.57.
What is Exozymes's market cap?
Exozymes was worth $37.13M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is EXOZ's P/E ratio?
Exozymes lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.20), so it has no meaningful P/E ratio.
Does Exozymes pay a dividend?
No. Exozymes has not paid a cash dividend over the last twelve months.
How has EXOZ stock performed over the past year?
Including dividends, EXOZ returned -73.6% over the past year, against +12.4% for the S&P 500.
How many EXOZ shares are sold short?
0M shares were sold short at the latest FINRA report, 0.67% of the float, or 1.2 days of average trading volume.
Who are Exozymes's competitors?
Companies most similar to Exozymes by business, industry and size include DYAI, PLUR, ELOX, RXRX, HALO.
See a number that looks wrong?